Published TCIMAIL newest issue No.201
Maximum quantity allowed is 999
CAS RN: 545380-34-5 | Product Number: Q0109
QNZ
Purity: >98.0%(HPLC)
- EVP4593
- N4-(4-Phenoxyphenethyl)quinazoline-4,6-diamine
- N4-[2-(4-Phenoxyphenyl)ethyl]-4,6-quinazolinediamine
- 6-Amino-4-[2-(4-phenoxyphenyl)ethylamino]quinazoline
| Size | Unit Price | Belgium | Japan* |
Shipping Information
|
|---|---|---|---|---|
| 5MG |
55,00 €
|
Contact Us | 3 | |
| 25MG |
193,00 €
|
Contact Us | 2 |
* Stock available in Belgium: Shipment on the same day
* Stock available in Japan: Please check the Shipping Simulation for estimated shipments. (excludes regulated items and dry ice shipments)
| Product Number | Q0109 |
Purity / Analysis Method
|
>98.0%(HPLC) |
| Molecular Formula / Molecular Weight | C__2__2H__2__0N__4O = 356.43 |
| Physical State (20 deg.C) | Solid |
Storage Temperature
|
Refrigerated (0-10°C) |
| Store Under Inert Gas | Store under inert gas |
| Condition to Avoid | Light Sensitive,Air Sensitive,Heat Sensitive |
| CAS RN | 545380-34-5 |
| Reaxys Registry Number | 9350957 |
| PubChem Substance ID | 468592774 |
| MDL Number | MFCD06411436 |
| Appearance | White to Light yellow to Green powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Melting point | 182.0 to 186.0 °C |
| NMR | confirm to structure |
| Melting Point | 184 °C |
| Pictogram |
|
| Signal Word | Warning |
| Hazard Statements | H315 : Causes skin irritation. H319 : Causes serious eye irritation. H413 : May cause long lasting harmful effects to aquatic life. |
| Precautionary Statements | P501 : Dispose of contents/ container to an approved waste disposal plant. P273 : Avoid release to the environment. P264 : Wash skin thoroughly after handling. P280 : Wear protective gloves/ eye protection/ face protection. P337 + P313 : If eye irritation persists: Get medical advice/ attention. P332 + P313 : If skin irritation occurs: Get medical advice/ attention. |
| HS Number | 2933599590 |
References
- Discovery of quinazolines as a novel structural class of potent inhibitors of NF-κB activation
- Regorafenib induces extrinsic and intrinsic apoptosis through inhibition of ERK/NF-κB activation in hepatocellular carcinoma cells
- The Selection of NFκB Inhibitors to Block Inflammation and Induce Sensitisation to FasL-Induced Apoptosis in HNSCC Cell Lines Is Critical for Their Use as a Prospective Cancer Therapy
Safety Data Sheet (SDS)
The requested SDS is not available.
Please Contact Us for more information.
The requested SDS is not available.
Specifications
The requested specifications are not available.
Please Contact Us for more information.
The requested specifications are not available.
C of A & Other Certificates
Please check that the lot number you have entered is correct. It is 4-5 alphanumeric characters before the hyphen. In particular, please check O (letter) or 0 (number) and I (letter) or 1 (number).
If your information is correct and you are still not able to view the requested certificates, Please Contact Us for more information.
Please check that the lot number you have entered is correct. It is 7 alphanumeric characters. In particular, please check O (letter) or 0 (number) and I (letter) or 1 (number).
Sample C of A
A sample C of A for this product is not available at this time.
Analytical Charts
The requested analytical chart is not available. Sorry for the inconvenience.